• Home
  • Pregnancy &           
  • Bookshop
  • Contact us
  • Donate now
  • Frequently Asked Questions
  • Please read

Our Helplines

1-877-439-2744 Motherisk Helpline
1-800-436-8477 Morning Sickness
1-877-327-4636 Alcohol and Substance
1-866-937-7678 Exercise in Pregnancy
1-888-246-5840 HIV and HIV Treatment
416-813-6780 Motherisk Helpline

The Cancer in Pregnancy Forum

Archived Questions and Answers
This Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
Submit a question
Forum > Cancer - Active Topics: Cancer - Active Topics
Exposure To Temozolomide For The Treatment Of Glioblastoma In Pregnancy

Date: 2008-12-11

Hello- I am wondering if there are any registries or other data sources regarding perinatal outcomes of fetuses exposed to Temazolamide? (Case = 25 weeks GA with nonoperable recurrence of gliobastoma). Thank-you


If you are a patient, consult your physician. The following information should not replace the assessment and advice you have been receiving from your physician (cancer specialist, obstetrician, or any other healthcare provider). It is offered for your information only.

Temozolomide (Temodol) is an antineoplastic agent used for the treatment of adults diagnosed with glioblastoma in conjunction with radiotherapy. It has low plasma protein binding (much of it will remain free and available in the plasma) and a short elimination half-life. It is a pro-drug and gets metabolized to MTIC which exerts its cytotoxic effect on the tumor by alkylation of the DNA. Animal studies in rats and rabbits showed numerous malformations. Human data are scarce, and it is not known whether temozolomide crosses the placenta; however the low molecular size of the compound and its low binding to protein suggests that it is capable of crossing to the fetus and embryo.

The recommended treatment is 42 days of consecutive therapy with temozolomide followed by an increased dose for 6 cycles (five consecutive days in each 4 week cycle). Therefore exposure can occur throughout most of gestation. Women of childbearing age should prevent pregnancy; however if pregnancy does occur when receiving treatment, treatment should not be discontinued, but women should be advised of the unknown but potentially high risk to the embryo/fetus

Valid XHTML 1.0 Transitional [Valid RSS]

* - "MOTHERISK - Treating the mother - Protecting the unborn" is an official mark of The Hospital for Sick Children. All rights reserved.

The information on this website is not intended as a substitute for the advice and care of your doctor or other health-care provider. Always consult your doctor if you have any questions about exposures during pregnancy and before you take any medications.

Copyright © 1999-2015 The Hospital for Sick Children (SickKids). All rights reserved.

The Hospital for Sick Children (SickKids) is a health-care, teaching and research centre dedicated exclusively to children; affiliated with the University of Toronto. For general inquires please call: 416-813-1500.

  |  Contact SickKids  |  Terms of Use